Literature DB >> 265731

Early central nervous system involvement in adults with acute non-myelogenous leukaemia.

T A Lister, J M Whitehouse, M E Beard, A Paxton, R L Brearley, L Brown, P F Wrigley, D Crowther.   

Abstract

Of 47 consecutive patients aged 15-60 years with acute non-myelogenous leukaemia (ANML) (40 acute lymphoblastic leukaemia (ALL); 5 acute Burkitt-like leukaemia (ABLL), 2 acute undifferentiated leukaemia (AUL) treated with a standard chemotherapy protocol (OPAL), 31 achieved complete remission (28/40(70%) of patients with ALL). CNS leukaemia occurred in 4/16 non-remitters, and in 6 patients who achieved complete remission (CR). CNS leukaemia occurred in all 5 patients with acute Burkitt-like leukaemia. 4/28 patients with ALL achieving CR had evidence of CSF involvement on cytocentrifuge examination shortly after CR. The apparent risk of early CNS disease suggests that prophylactic CNS therapy should be given early in the treatment of acute non-myelogenous leukaemia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 265731      PMCID: PMC2025338          DOI: 10.1038/bjc.1977.71

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  PHASE II STUDY OF A-8103 (NSC-25154) IN ACUTE LEUKEMIA IN ADULTS.

Authors:  J S HEWLETT; J D BATTLE; R C BISHOP; W M FOWLER; S O SCHWARTZ; P S HAGEN; J LOUIS
Journal:  Cancer Chemother Rep       Date:  1964-11

2.  Evaluation of induction of remission, intensification, and central nervous system prophylactic treatment in acute lymphoblastic leukemia.

Authors:  F Sackmann Muriel; S Pavlovsky; J A Peñalver; G Hidalgo; A Cebrian Bonesana; M Eppinger-Helft; G H De Macchi; A Pavlovsky
Journal:  Cancer       Date:  1974-08       Impact factor: 6.860

3.  The incidence of central nervous system leukemia in adults with acute leukemia.

Authors:  R W Wolk; S R Masse; R Conklin; E J Freireich
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

4.  A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood acute lymphocytic leukemia.

Authors:  R J Aur; J V Simone; H O Hustu; M S Verzosa
Journal:  Cancer       Date:  1972-02       Impact factor: 6.860

5.  Factors that influence the appearance of central nervous system leukemia.

Authors:  S Pavlovsky; M Eppinger-Helft; F Sackmann Muriel
Journal:  Blood       Date:  1973-12       Impact factor: 22.113

6.  Comparison of two methods of preventing central nervous system leukemia.

Authors:  R J Aur; H O Hustu; M S Verzosa; A Wood; J V Simone
Journal:  Blood       Date:  1973-09       Impact factor: 22.113

7.  Acute lymphocytic leukemia in children.

Authors:  J V Simone; R J Aur; H O Hustu; M Verzosa
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

8.  Treatment of acute leukemia in adults.

Authors:  B D Clarkson; M D Dowling; T S Gee; I B Cunningham; J H Burchenal
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

  8 in total
  4 in total

1.  Transient sixth-nerve palsy as the first presentation of acute leukaemia.

Authors:  L Averbuch-Heller; S Gillis; T Ben-Hur
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

2.  A longitudinal electroencephalographic study in acute leukaemia.

Authors:  G Sideri; A Bollea; M Prencipe; F Giona; L Granati; A Pazzaglini
Journal:  Ital J Neurol Sci       Date:  1981-05

3.  Treatment of adult lymphoblastic leukaemia using cyclical chemotherapy with three combinations of four drugs (COAP, POMP, TRAP schedule).

Authors:  S J Proctor; R Finney; W Walker; R B Thompson
Journal:  Postgrad Med J       Date:  1981-01       Impact factor: 2.401

4.  Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukaemia and lymphoma.

Authors:  J Tucker; P F Prior; C R Green; G M Ede; J F Stevenson; J Gawler; G A Jamal; M Charlesworth; C M Thakkar; P Patel
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.